Thymosin alpha 1,
does it really help with Improved survival and disease-free survival as an adjunct to cancer treatment?
research showsThymosin alpha 1 as an adjunct to cancer therapy is rated C for improving survival or disease-free survival. In the Cochrane review, overall survival was RR 1.21 (95% CI 0.94 to 1.56) and disease-free survival was RR 3.37 (95% CI 0.66 to 17.30). Both point estimates favored benefit but crossed the null. Direct human survival data therefore exist, making D too harsh, but the trials were small, old, at moderate risk of bias, and highly imprecise. The evidence is limited and inconclusive, giving lower C with 41 points.
ads claimMarketing connects immune-cell counts, fewer infections, or treatment tolerance directly to prevented recurrence and longer life. Biological immunomodulation is not equivalent to demonstrated clinical survival benefit.
Useful facts when choosing a product
- Thymosin alpha 1 is a 28-amino-acid immunomodulatory peptide administered subcutaneously as the synthetic drug thymalfasin.
- Prescription indications and dosing vary by country and product, so the specific label and treating oncologist's instructions take priority.
- Evidence that an adjunct changes immune markers or infections addresses a different question from whether it prolongs cancer survival.
- Injection-site pain or erythema and hypersensitivity can occur, and specialist judgment is required in immune disease, transplantation, or immunosuppressive treatment.
Chamgap Semantic Classification Code
Candidate index · review held
M.thymosin-alpha-1.UNK.survival-and-disease-free-survival-as-an-adjunct-to-cancer-treatment.improve.UNKMedicinal interventions > Thymosin alpha 1 > Unknown > survival and disease-free survival as an adjunct to cancer treatment > Improvement claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Wolf 2011 reviewed 26 randomized trials with 2,736 adults receiving thymic peptides alongside chemotherapy or radiotherapy. Only six assessed synthetic peptides including thymosin alpha 1, and survival estimates were imprecise and nonsignificant. Gish 2009 randomized only 25 patients with unresectable hepatocellular carcinoma to TACE with or without thymalfasin; survival and response were numerically higher but underpowered. Later observational and immune-marker studies cannot establish causal survival benefit.
Why this is classified as C (41)
C. Overall survival RR 1.21 (95% CI 0.94 to 1.56) and disease-free survival RR 3.37 (95% CI 0.66 to 17.30) crossed the null but had point estimates favoring benefit, and direct human survival data exist. That makes D too harsh. Small, old trials, moderate risk of bias, and very wide intervals keep the evidence inconclusive and limit it to lower C with 41 points. Injection-site reactions, hypersensitivity, and limited long-term safety evidence remain separate from efficacy.
Counterpoint. A sufficiently powered, double-blind trial using current standard therapy and directly measuring recurrence and death in a defined cancer could change this verdict.
Rejudgment record. Reassessment (cross-check reflected) — Applied C because pooled overall- and disease-free-survival point estimates favored benefit and direct human survival data exist, while both intervals crossed the null and the trials were small, old, moderately biased, and imprecise
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved survival and disease-free survival as a cancer adjunct | C | Cochrane overall survival RR 1.21 crossed the null, and the small, old evidence is inconclusive. |
| Improved immune markers | ? | Immune markers are surrogates for survival, and clinical benefit is unconfirmed. |
| Benefit in a specific cancer or treatment subgroup | ? | Confirmatory subgroup evidence is absent. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Wolf E et al. 2011 | Cochrane systematic review and meta-analysis | 26 trials and 2,736 participants; six synthetic-peptide trials | Cochrane academic review | Overall survival, disease-free survival, tumor response, and toxicity | Thymosin-alpha-1 OS RR was 1.21 (0.94 to 1.56) and DFS RR was 3.37 (0.66 to 17.30), both nonsignificant. | Key synthesis of direct survival outcomes |
| Gish RG et al. 2009 | Randomized controlled pilot trial | 25 patients with unresectable hepatocellular carcinoma | Product-development support reported | Survival, tumor response, and infections | The TACE combination was numerically favorable, but the sample was too small to establish survival benefit. | Small exploratory evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-19).
Final verification and publication gate: Codex · Evidence date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Thymosin alpha 1 x improved cancer survival and disease-free survival — Evidence Grade C·41. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/thymosin-alpha-1-cancer-survival-disease-free-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.